{"id":"W2182872902","doi":"10.1111/bjh.13855","title":"A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone ( <scp>CEOP</scp> ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( <scp>PTCL</scp> ): final results from the T‐ cell consortium trial","year":2015,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Genentech; Spectrum Pharmaceuticals","keywords":"Vincristine; Etoposide; Medicine; Cyclophosphamide; Prednisone; Lymphoma; Internal medicine; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008503536,0.0006534888,0.002101535,0.0001610653,0.000354247,0.0001539642,0.0004131451,0.0002548172,0.000004936053],"category_scores_gemma":[0.00191895,0.0004537181,0.0002557707,0.000219414,0.000363376,0.0002907025,0.0001512962,0.0003496464,0.000002972196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002289505,"about_ca_system_score_gemma":0.001032929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002090178,"about_ca_topic_score_gemma":0.0005028191,"domain_scores_codex":[0.9948571,0.0004514326,0.002042435,0.0007810761,0.001072829,0.0007950783],"domain_scores_gemma":[0.9917262,0.002934227,0.002845283,0.0005090808,0.001384823,0.0006003625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.09949318,0.1634123,0.5460961,0.0004385498,0.007707365,0.0501827,0.04471727,0.000339317,0.0005077923,0.00003289124,0.05932038,0.02775209],"study_design_scores_gemma":[0.7962459,0.1075997,0.051316,0.001085418,0.001861348,0.01652496,0.008501696,0.000266027,0.01105587,0.0001439239,0.005245772,0.0001534182],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854326,0.009261117,0.00007471212,0.0001637779,0.0004793594,0.003610335,0.0005022511,0.0000394687,0.0004364015],"genre_scores_gemma":[0.9943722,0.0009057304,0.00291512,0.0003038264,0.000418967,0.000191244,0.0001742488,0.0001094404,0.0006092112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6967527,"threshold_uncertainty_score":0.9997914,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02110693813914477,"score_gpt":0.2709042396403967,"score_spread":0.249797301501252,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}